We recently published an article titled Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Private Advisor Group LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 75.4% during the 4th ...

Highlights,The New York State Common Retirement Fund raised its stake in ImmunityBio by 62.8% in the fourth quarter.,Several ...

ImmunityBio (IBRX) delivered earnings and revenue surprises of 42.31% and 13.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $30.00 target price ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against the other stocks. The stock market kicked off the trading week in a bloodbath, erasing last week ...